

Immunoglobulins power 12% surge in Indian private vaccine market growth: Pharmarack

28 November 2025 | News

Human Normal Immunoglobulin led the segment at Rs 279.38 crore with 12% growth



The vaccines market reached Rs 2,217.28 crore in MAT October 2025, registering a strong 12% growth. Human Normal Immunoglobulin led the segment at Rs 279.38 crore with 12% growth, followed by Anti-Rabies Vaccine at Rs 263.67 crore (+15%) and Influenza Vaccine at Rs 253.79 crore (+14%), according to Sheetal Sapale, Vice President – Commercial at Pharmarack Technologies.

Combination vaccines with tetanus components grew 20% to Rs 199.88 crore, while pneumonia vaccines rose 14% to Rs 171.13 crore. Meningococcal vaccines delivered a robust 24% increase, reaching Rs 146.84 crore.

Sheetal Sapale noted impressive surges in Typhoid and Paratyphoid vaccines, which jumped 49% to Rs 72.01 crore, Japanese Encephalitis Vaccine, which grew 95% to Rs 10.73 crore, and Hepatitis Immunoglobulin, which saw the highest spike at 97% to Rs 29.91 crore. Core immunisation products such as DTP combinations, BCG, and MMR also continued to expand steadily.

However, she pointed out declines in several categories, including Hepatitis A (–11%), Varicella (–11%), Snake-bite Sera (–12%), Anti-Rabies Sera (–17%), and the DTP–HepB–Influenza multicomponent vaccine, which dropped sharply by 36% to Rs 7.43 crore.

Sheetal Sapale noted that post Covid, many hospitals had started stocking vaccines, as many patients preferred hospitals as vaccination centres. That trend has been gradually fading now and sales may be happening more at retailer counters.